Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

A. Francis, Prudence; Pagani, Olivia; F. Fleming, Gini; Walley, Barbara; Colleoni, Marco; Láng, István; Gómez, Henry; Tondini, Carlo; Ciruelos, Eva; J. Burstein, Harold; Bonnefoi, Hervé; Bellet, Meritxell; Martino, Silvana; E. Geyer, Charles; P. Goetz, Matthew; Stearns, Vered; Pinotti, Graziella; Puglisi, Fabio; Spazzapan, Simon; Ángel Climent, Miguel; Pavesi, Lorenzo; Ruhstaller, Thomas; E. Davidson, Nancy; L. Coleman, Robert; Debled, Marc; Buchholz, Stefan; N. Ingle, James; P. Winer, Eric; Maibach, Rudolf; Rabaglio, Manuela; Ruepp, Barbara; Di Leo, Angelo; S. Coates, Alan; D. Gelber, Richard; Goldhirsch, Aron; M. Regan, Meredith

doi:10.1056/nejmoa1803164

Public

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Published in New England Journal of Medicine • Jun 4, 2018

Authors:

Prudence A. Francis

Olivia Pagani

Gini F. Fleming

Abstract

BACKGROUND: In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those ...

Subject

Exemestane

Tamoxifen

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!